{"id":3334,"date":"2009-08-26T12:19:51","date_gmt":"2009-08-26T12:19:51","guid":{"rendered":"https:\/\/www.cornerstone.com\/?post_type=case_study&#038;p=3334"},"modified":"2023-12-12T14:38:28","modified_gmt":"2023-12-12T19:38:28","slug":"sec-v-biopure-corporation","status":"publish","type":"case_study","link":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/","title":{"rendered":"SEC v. Biopure Corporation"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","categories":[50,51,65,60],"tags":[],"asset_type":[79],"class_list":["post-3334","case_study","type-case_study","status-publish","hentry","category-corporate-and-government-investigations","category-corporate-governance","category-life-sciences","category-securities-litigation"],"acf":[],"yoast_head":"\n<title>SEC v. Biopure Corporation | Cornerstone Research<\/title>\n<meta name=\"description\" content=\"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SEC v. Biopure Corporation\" \/>\n<meta property=\"og:description\" content=\"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Cornerstone Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CornerstoneResearchInc\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-12T19:38:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/greenlogo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"210\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Cornerstone_Res\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/\",\"url\":\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/\",\"name\":\"SEC v. Biopure Corporation | Cornerstone Research\",\"isPartOf\":{\"@id\":\"https:\/\/www.cornerstone.com\/#website\"},\"datePublished\":\"2009-08-26T12:19:51+00:00\",\"dateModified\":\"2023-12-12T19:38:28+00:00\",\"description\":\"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cornerstone.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SEC v. Biopure Corporation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cornerstone.com\/#website\",\"url\":\"https:\/\/www.cornerstone.com\/\",\"name\":\"Cornerstone Research\",\"description\":\"Economic and Financial Consulting and Expert Testimony\",\"publisher\":{\"@id\":\"https:\/\/www.cornerstone.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cornerstone.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cornerstone.com\/#organization\",\"name\":\"Cornerstone Research\",\"url\":\"https:\/\/www.cornerstone.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg\",\"contentUrl\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg\",\"width\":1000,\"height\":61,\"caption\":\"Cornerstone Research\"},\"image\":{\"@id\":\"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CornerstoneResearchInc\",\"https:\/\/x.com\/Cornerstone_Res\",\"https:\/\/www.linkedin.com\/company\/cornerstone-research\/\"]}]}<\/script>\n","yoast_head_json":{"title":"SEC v. Biopure Corporation | Cornerstone Research","description":"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/","og_locale":"en_US","og_type":"article","og_title":"SEC v. Biopure Corporation","og_description":"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.","og_url":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/","og_site_name":"Cornerstone Research","article_publisher":"https:\/\/www.facebook.com\/CornerstoneResearchInc","article_modified_time":"2023-12-12T19:38:28+00:00","og_image":[{"width":300,"height":210,"url":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/greenlogo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Cornerstone_Res","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/","url":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/","name":"SEC v. Biopure Corporation | Cornerstone Research","isPartOf":{"@id":"https:\/\/www.cornerstone.com\/#website"},"datePublished":"2009-08-26T12:19:51+00:00","dateModified":"2023-12-12T19:38:28+00:00","description":"In litigation brought by the Securities and Exchange Commission (SEC) against Biopure Corporation (Biopure) and several current and former officers of the company involving its drug Hemopure, counsel for Biopure retained Cornerstone Research to work with Professor Paul Gompers of Harvard Business School.","breadcrumb":{"@id":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cornerstone.com\/insights\/cases\/sec-v-biopure-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cornerstone.com\/"},{"@type":"ListItem","position":2,"name":"SEC v. Biopure Corporation"}]},{"@type":"WebSite","@id":"https:\/\/www.cornerstone.com\/#website","url":"https:\/\/www.cornerstone.com\/","name":"Cornerstone Research","description":"Economic and Financial Consulting and Expert Testimony","publisher":{"@id":"https:\/\/www.cornerstone.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cornerstone.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cornerstone.com\/#organization","name":"Cornerstone Research","url":"https:\/\/www.cornerstone.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg","contentUrl":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg","width":1000,"height":61,"caption":"Cornerstone Research"},"image":{"@id":"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CornerstoneResearchInc","https:\/\/x.com\/Cornerstone_Res","https:\/\/www.linkedin.com\/company\/cornerstone-research\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/case_study\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":2,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/case_study\/3334\/revisions"}],"predecessor-version":[{"id":8061,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/case_study\/3334\/revisions\/8061"}],"wp:attachment":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/tags?post=3334"},{"taxonomy":"asset_type","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/asset_type?post=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}